JP2024514339A5 - - Google Patents

Info

Publication number
JP2024514339A5
JP2024514339A5 JP2023564025A JP2023564025A JP2024514339A5 JP 2024514339 A5 JP2024514339 A5 JP 2024514339A5 JP 2023564025 A JP2023564025 A JP 2023564025A JP 2023564025 A JP2023564025 A JP 2023564025A JP 2024514339 A5 JP2024514339 A5 JP 2024514339A5
Authority
JP
Japan
Prior art keywords
substituted
group
optionally substituted
membered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514339A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025083 external-priority patent/WO2022221704A1/en
Publication of JP2024514339A publication Critical patent/JP2024514339A/ja
Publication of JP2024514339A5 publication Critical patent/JP2024514339A5/ja
Pending legal-status Critical Current

Links

JP2023564025A 2021-04-16 2022-04-15 がんを治療する化合物、組成物、及び方法 Pending JP2024514339A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163175974P 2021-04-16 2021-04-16
US63/175,974 2021-04-16
US202163281493P 2021-11-19 2021-11-19
US63/281,493 2021-11-19
PCT/US2022/025083 WO2022221704A1 (en) 2021-04-16 2022-04-15 Compounds, compositions and methods of treating cancer

Publications (2)

Publication Number Publication Date
JP2024514339A JP2024514339A (ja) 2024-04-01
JP2024514339A5 true JP2024514339A5 (https=) 2025-04-23

Family

ID=81580947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564025A Pending JP2024514339A (ja) 2021-04-16 2022-04-15 がんを治療する化合物、組成物、及び方法

Country Status (14)

Country Link
US (1) US20240228482A1 (https=)
EP (1) EP4323358A1 (https=)
JP (1) JP2024514339A (https=)
KR (1) KR20240037184A (https=)
AU (1) AU2022256514A1 (https=)
BR (1) BR112023021068A2 (https=)
CA (1) CA3215395A1 (https=)
CL (1) CL2023003068A1 (https=)
CO (1) CO2023015484A2 (https=)
IL (1) IL307732A (https=)
MX (1) MX2023012245A (https=)
PE (1) PE20240767A1 (https=)
TW (1) TW202309023A (https=)
WO (1) WO2022221704A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4359381A4 (en) * 2021-06-21 2025-04-30 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
US20250042896A1 (en) * 2021-10-29 2025-02-06 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Polycyclic compound as cbl-b inhibitor
AU2022379959A1 (en) 2021-11-05 2024-05-09 Genentech, Inc. Lactams as cbl-b inhibitors selective over c-cbl
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
EP4554570A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent
AU2023307165A1 (en) * 2022-07-12 2025-02-06 Hotspot Therapeutics, Inc. Methods of preparation of heterocyclic compounds
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
CA3261875A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR
EP4558504A1 (en) * 2022-07-18 2025-05-28 Insilico Medicine IP Limited Cbl-b inhibitors and methods of uses thereof
WO2024077236A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024077244A1 (en) * 2022-10-07 2024-04-11 Hotspot Therapeutics, Inc. Compounds, compositions and methods of treating disorders
WO2024086730A1 (en) * 2022-10-19 2024-04-25 Hotspot Therapeutics, Inc. Heterocyclic cbl-b inhibitors for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024131939A1 (en) * 2022-12-23 2024-06-27 Insilico Medicine Ip Limited Cbl-b inhibitors and methods of uses thereof
EP4653436A1 (en) * 2023-01-19 2025-11-26 Guangzhou Yufan Nantu Biotechnologies Co., Ltd Heterocyclic compounds, preparation method therefor and use thereof
CN120530105A (zh) * 2023-01-20 2025-08-22 海南先声再明医药股份有限公司 取代的三环化合物及其应用
WO2024227436A1 (en) * 2023-05-04 2024-11-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025067342A1 (zh) * 2023-09-27 2025-04-03 北京望实智慧科技有限公司 用作Cbl-b抑制剂的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740837A1 (de) * 1987-11-27 1989-06-08 Schering Ag Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel
MY150032A (en) * 2007-07-19 2013-11-29 Merck Sharp & Dohme Heterocyclic amide compounds as protein kinase inhibitors
AU2008317353B2 (en) * 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
CA3041650A1 (en) * 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
WO2019131575A1 (ja) * 2017-12-26 2019-07-04 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除剤
CA3136348A1 (en) * 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
MX2021015675A (es) * 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
JP2020169215A (ja) * 2020-07-15 2020-10-15 住友化学株式会社 複素環化合物を用いる有害節足動物防除方法
EP4554570A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent
AU2023307165A1 (en) * 2022-07-12 2025-02-06 Hotspot Therapeutics, Inc. Methods of preparation of heterocyclic compounds
CA3261875A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR
EP4554586A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
WO2024015863A1 (en) * 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation

Similar Documents

Publication Publication Date Title
JP2024514339A5 (https=)
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
AU2015207757B8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
JP2022124458A5 (https=)
JP7592689B2 (ja) Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用
JP7668777B2 (ja) 癌治療
JP2017515802A5 (https=)
JP2006507265A5 (https=)
JP2001527066A5 (https=)
JP2020532556A (ja) 癌を処置するための併用療法
JP2003522163A5 (https=)
JP2000302693A (ja) 突然死予防のためのコルチコトロピン放出因子アンタゴニスト
JP2021524835A5 (https=)
JPWO2021060453A5 (https=)
CN114867622A (zh) 涉及二芳基巨环化合物的组合疗法
JP2018534288A5 (https=)
JP2012513390A5 (https=)
CN110840893A (zh) 含克莱拉尼的药物组合物及其用途
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
JP2016514727A5 (https=)
JPWO2021187548A5 (https=)
JP2022535609A5 (https=)
JP2015516980A5 (https=)
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
KR920016418A (ko) Nmda 길항제